Cabergoline, a potent dopamine agonist primarily used in the treatment of hyperprolactinemia, exhibits various pharmacological actions that make it effective in managing conditions associated with excess prolactin levels. Manufactured by Astera Labs, this medication functions by binding to dopamine D2 receptors in the pituitary gland, thereby inhibiting the secretion of prolactin from lactotroph cells.
For more detailed information, visit this link.
Mechanism of Action
The pharmacological action of cabergoline involves:
- Dopamine receptor activation: Cabergoline selectively activates D2 receptors, leading to a decrease in prolactin release.
- Prolactin level reduction: By lowering prolactin levels, cabergoline helps in the treatment of conditions such as infertility and menstrual disturbances.
- Extended half-life: Cabergoline has a longer half-life compared to other dopamine agonists, allowing for convenient dosing schedules.
Clinical Applications
Cabergoline is indicated for:
- Hyperprolactinemia
- Prolactin-secreting pituitary adenomas
- Acromegaly, in combination with other therapies
Side Effects and Considerations
While cabergoline is generally well-tolerated, some users may experience side effects such as:
- Nausea
- Dizziness
- Fatigue
- Potential cardiovascular effects with long-term use
It is crucial for patients to consult with healthcare professionals for proper guidance and monitoring during treatment.
